Fri 21'st Apr 2017
Spark Therapeutics Stock Analysis
Technical stock analysis for Fri 21'st Apr 2017
Sell candidate since 2017-04-21
Spark Therapeutics lies in the middle of a wide and strong falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -19.4% during the next 3 months and, with 90% probability hold a price between USD 35.48 and USD 45.69 at the end of this period.
There are few to none technical positive signals at the moment. Spark Therapeutics holds sales signals from both short- and long-term moving averages. In addition, there is a general sales signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up there will be some resistance from the lines at USD 52.62 and USD 54.50. A break-up above any of these levels will issue buy signals. A sales signal was issued from a pivot top point on Thursday April 20, 2017, which indicates further falls until a new bottom pivot has been found. Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.
Relative Strength Index (RSI)
RSI14 is 47 and the stock is currently not being overbought or oversold
Support & Resistance
Spark Therapeutics finds support from accumulated volume at USD 52.35, USD 51.49, and USD 51.09. On the upside the stock meets some resistance from accumulated volume at USD 63.06, USD 61.38 and USD 57.63.
This stock is usually traded at good volume, and with minor daily changes the risk is considered to be low. During the last day, the stock moved USD 2.17 (4.17%) between high and low. For the last week, the stock has had a daily average volatility of 4.79%.
Our recommended stoploss: We hold a sell evaluation for this stock. No stop-loss set.
Spark Therapeutics holds several negative signals and is within a wide and strong falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our recommendation for this stock since last evaluation from a Hold/Accumulate to a Sell Candidate.